Key statistics
On Friday, C4 Therapeutics Inc (CCCC:NSQ) closed at 6.06, 471.70% above the 52 week low of 1.06 set on Dec 06, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.06 |
---|---|
High | 6.17 |
Low | 5.89 |
Bid | 5.90 |
Offer | 6.06 |
Previous close | 6.04 |
Average volume | 1.06m |
---|---|
Shares outstanding | 70.59m |
Free float | 62.43m |
P/E (TTM) | -- |
Market cap | 427.77m USD |
EPS (TTM) | -1.70 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
- C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
- C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting
- C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.
- C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
- C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
- C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen
- C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
- C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
More ▼